Alaunos Therapeutics, Inc. Payments for Repurchase of Equity
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Alaunos Therapeutics, Inc. payments for repurchase of equity for the quarter ending 2018-09-30 was $0.00.
- Alaunos Therapeutics, Inc. payments for repurchase of equity for the quarter ending 2018-06-30 was $544.00K.
- Alaunos Therapeutics, Inc. payments for repurchase of equity for the quarter ending 2018-03-31 was $731.00K.
- Alaunos Therapeutics, Inc. payments for repurchase of equity for the quarter ending 2017-09-30 was $0.00.
- Alaunos Therapeutics, Inc. payments for repurchase of equity for fiscal 2016 was $1.50M, a 189.58% increase from fiscal 2015.
- Alaunos Therapeutics, Inc. payments for repurchase of equity for fiscal 2015 was $518.00K, a 4.78% decline from fiscal 2014.
- Alaunos Therapeutics, Inc. payments for repurchase of equity for fiscal 2014 was $544.00K, a 9.24% increase from fiscal 2013.
- Alaunos Therapeutics, Inc. payments for repurchase of equity for fiscal 2013 was $498.00K.
| Period end | Payments for Repurchase of Equity 3 month | Payments for Repurchase of Equity 12 month |
|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | |
| 2018-06-30 | $544.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | |
| 2018-03-31 | $731.00K 10-Q · filed 2018-05-10 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | |
| 2016-12-31 | $647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $1.50M 10-K · filed 2017-02-16 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $992.00K derived: sum of 4 quarters · filed 2017-11-06 |
| 2016-06-30 | $851.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-31 | $1.13M derived: sum of 4 quarters · filed 2017-07-31 |
| 2016-03-31 | $2.00K 10-Q · filed 2017-05-01 | $274.00K derived: sum of 4 quarters · filed 2017-05-01 |
| 2015-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $518.00K 10-K · filed 2017-02-16 |
| 2015-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $791.00K derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | |
| 2015-03-31 | $246.00K 10-Q · filed 2016-05-10 | |
| 2014-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $544.00K 10-K · filed 2017-02-16 |
| 2013-12-31 | $498.00K 10-K · filed 2016-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |